

What is known about the epidemiology of Acute Flaccid Myelitis


Janell Routh, MD MHS

AFM and Domestic Polio Team Lead Division of Viral Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention

AFM Symposium


June 5, 2020

Surveillance for AFM is challenging




cough and fever

Surveillance for AFM is challenging



Case definition for AFM



Confirmed case of AFM – Acute onset of flaccid limb

weakness, AND an MRI showing a spinal cord lesion largely restricted to gray matter and spanning one or

* Excluding persons with gray matter lesions in the spinal cord resulting from physician diagnosed malignancy, vascular disease, or anatomic abnormality.

AFM surveillance processes involve clinicians and health departments

Clinician reports patient suspected to have AFM to Health Department



Health department
(HD) verifies patient
meets criteria and
reports to CDC



HD collects medical information, MRIs and coordinates specimens to send to CDC



Neurology panel reviews information and images and provides a case classification



Surveillance classification communicated to HD and then HD relays classification to clinician

Clinical diagnosis and public health surveillance have different purposes

Clinical Diagnosis


- Patient-level
- Used for individual clinical management decisions
- Time-sensitive
- Diagnosis based on full clinical presentation
- Aim for the most accurate diagnosis

Public Health Surveillance

- Population-level
- Use of standardized case definitions
- Measures disease burden and trends over time
- Delayed reporting and classification
- Balances sensitivity and specificity


National increase in AFM cases every 2 years since 2014

Number of confirmed reported AFM cases, Aug 2014 – May 2020 (n=625)




Month of onset

AFM cases, 2005-2014, 5 sites combined, United States




Cortese MM, Kambhampati AK, Schuster JE, et.al. A ten-year retrospective evaluation of AFM at 5 pediatric centers in the US, 2005 – 2014. PLOS One. January, 2020.

AFM has multiple causes




U.S. surveillance shows a consistent baseline rate of AFM Number of confirmed reported AFM cases, Aug 2014 – May 2020 (n=625)



What is causing the biennial peaks in AFM?


Number of confirmed reported AFM cases, Aug 2014 – May 2020 (n=625)




Month of limb weakness onset

2018 was the most recent peak year for AFM

Number of confirmed reported AFM cases, January – December, 2020 (n=238)




Demographic characteristics of confirmed AFM cases, 2018




Data current as of June 1, 2020 Icon Credits: Juan Pablo Bravo; Marie Van de Broeck; DT Design; MRFA

No geographic clustering of AFM among 238 cases in 42 states




Clinical Characteristics of confirmed AFM cases, 2018




Data current as of June 1, 2020 Icon credits: Aldric Rodriguez; ProSymbols; Tawny Whatmore

Symptoms consistent with a viral illness precede limb weakness

Days from symptom onset to limb weakness Median (IQR)




Proportion of cases



AFM diagnostic testing remains low yield


CDC testing results, 2018



*Some patients had multiple positive specimens


Lopez, et al. Vital Signs: Surveillance for Acute Flaccid Myelitis – US, 2018, MMWR 2019

What is causing the biennial peaks in AFM?



Month of limb weakness onset


AFM case characteristics in peak years differ from those in non-peak years



Peak years (2016, 2018) Non-peak years (2015, 2017)

McLaren, et.al. Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015 – 2018. EID, Vol 26; February 2020.

AFM case characteristics also differ between peak years




McLaren, et.al. Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015 – 2018. EID, Vol 26; February 2020.

Summary


- Causes of AFM in peak years appear different from those in non-peak years, but even in peak years there may be multiple causes
- Differences in EV and EV-D68 detection support an association in peak years
 - Detection of two main EV types in 2018 emphasize need for clinical surveillance plus laboratory surveillance to understand the full spectrum of AFM
- Underlying mechanism of disease remains the critical unknown
 - If EV-D68 is the primary driver in peak years, why does paralysis develop rarely?
 - Do different case characteristics give clues about disease mechanism?
 - Understanding disease mechanisms for AFM will allow for treatment and prevention strategies to move forward

What do we expect for AFM in 2020?



Month of limb weakness onset

Current number of suspect AFM cases reported to CDC is typical of both peak and non-peak years for this time period



Thank you!

Acknowledgments

Sarah Kidd	Steve Oberste	Mark Pallansch
Adriana Lopez	Will Weldon	Glen Abedi
Adria Lee	Jennifer Anstadt	Cate Otten
Manisha Patel	Alan Nix	Brian Emery
Susannah McKay	Shannon Rogers	Jessica Ciomperlik
Margaret Cortese	Sue Tong	AFM Response Team
Margaret Cortese Eileen Yee	Sue Tong Grace Gombolay	AFM Response Team Kim Hetzler
C	C	•

Sarah Hopkins

What is known about the viruses involved in AFM



Charles Chiu, MD, PhD.

Professor, Laboratory Medicine and Medicine Division of Infectious Diseases Director, UCSF-Abbott Viral Diagnostics and Discovery Center Associate Director, UCSF Clinical Microbiology Laboratory University of California San Francisco